These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice. Su J; Sherman A; Doerfler PA; Byrne BJ; Herzog RW; Daniell H Plant Biotechnol J; 2015 Oct; 13(8):1023-32. PubMed ID: 26053072 [TBL] [Abstract][Full Text] [Related]
29. Treating lysosomal storage disorders: What have we learnt? Lachmann RH J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601 [TBL] [Abstract][Full Text] [Related]
30. Fetal therapies and trials for lysosomal storage diseases: a survey of attitudes of parents and patients. Schwab ME; Brown JEH; Lianoglou B; Jin C; Conroy PC; Gallagher RC; Harmatz P; MacKenzie TC Orphanet J Rare Dis; 2022 Jan; 17(1):25. PubMed ID: 35093147 [TBL] [Abstract][Full Text] [Related]
31. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405 [TBL] [Abstract][Full Text] [Related]
32. Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives. Solomon M; Muro S Adv Drug Deliv Rev; 2017 Sep; 118():109-134. PubMed ID: 28502768 [TBL] [Abstract][Full Text] [Related]
33. Pregnancy and associated events in women receiving enzyme replacement therapy for late-onset glycogen storage disease type II (Pompe disease). Rohman PJ; Scott E; Richfield L; Ramaswami U; Hughes DA J Obstet Gynaecol Res; 2016 Oct; 42(10):1263-1271. PubMed ID: 27384519 [TBL] [Abstract][Full Text] [Related]
34. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases. Li M Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286 [TBL] [Abstract][Full Text] [Related]
35. Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation. But WM; Lee SH; Chan AO; Lau GT Hong Kong Med J; 2009 Dec; 15(6):474-7. PubMed ID: 19966354 [TBL] [Abstract][Full Text] [Related]
36. Quantitative computed tomography for enzyme replacement therapy in Pompe disease. Yonee C; Toyoshima M; Young SP; Maruyama S; Higuchi I; Narita A; Maegaki Y; Nanba E; Ohno K; Kawano Y Brain Dev; 2012 Nov; 34(10):834-9. PubMed ID: 22521436 [TBL] [Abstract][Full Text] [Related]
37. Pompe disease: early diagnosis and early treatment make a difference. Chien YH; Hwu WL; Lee NC Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029 [TBL] [Abstract][Full Text] [Related]
38. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective. Thomas R; Kermode AR Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228 [TBL] [Abstract][Full Text] [Related]